AXQ Capital LP Acquires Shares of 31,298 Embecta Corp. $EMBC

AXQ Capital LP acquired a new stake in Embecta Corp. (NASDAQ:EMBC) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 31,298 shares of the company’s stock, valued at approximately $303,000. AXQ Capital LP owned 0.05% of Embecta at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of EMBC. Banque Transatlantique SA boosted its stake in Embecta by 879.1% in the 1st quarter. Banque Transatlantique SA now owns 3,701 shares of the company’s stock valued at $44,000 after buying an additional 3,323 shares in the last quarter. Brooklyn Investment Group lifted its holdings in shares of Embecta by 1,164.1% during the first quarter. Brooklyn Investment Group now owns 3,590 shares of the company’s stock valued at $46,000 after acquiring an additional 3,306 shares during the period. Wealthquest Corp acquired a new stake in shares of Embecta in the 1st quarter valued at $48,000. Picton Mahoney Asset Management acquired a new stake in shares of Embecta in the 1st quarter valued at $50,000. Finally, CWM LLC grew its holdings in shares of Embecta by 16.0% in the 2nd quarter. CWM LLC now owns 8,080 shares of the company’s stock worth $78,000 after purchasing an additional 1,115 shares during the last quarter. Institutional investors own 93.83% of the company’s stock.

Wall Street Analysts Forecast Growth

EMBC has been the subject of several analyst reports. Zacks Research downgraded shares of Embecta from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. BTIG Research reiterated a “buy” rating and issued a $25.00 target price on shares of Embecta in a research note on Friday, September 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Embecta currently has a consensus rating of “Hold” and a consensus price target of $19.00.

Embecta Price Performance

EMBC opened at $14.64 on Tuesday. Embecta Corp. has a fifty-two week low of $9.20 and a fifty-two week high of $21.48. The firm has a 50 day simple moving average of $14.08 and a 200 day simple moving average of $12.47. The company has a market cap of $856.29 million, a price-to-earnings ratio of 10.24, a price-to-earnings-growth ratio of 0.81 and a beta of 1.10.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.